FDA Approves 2 gMG Treatments, AR1001 Slows Decline in Monotherapy Group of POLARIS-AD Trial, Benjamin Greenberg's, MD, MHS, Insights From the 2026 RNDS
Source: NeurologyLive Published 21 Nov 2026 Imported 21 Nov 2026 Relevancy: Not reviewed
Read the article